Detalhe da pesquisa
1.
Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial.
Am J Respir Crit Care Med
; 198(5): 657-666, 2018 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29954183
2.
Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Eur Respir J
; 47(4): 1235-43, 2016 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-26965290
3.
Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
Eur Respir J
; 47(6): 1758-66, 2016 06.
Artigo
Inglês
| MEDLINE | ID: mdl-27076583
4.
Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis.
Bull World Health Organ
; 94(2): 147-52, 2016 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-26908964
5.
Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.
BMC Infect Dis
; 16(1): 453, 2016 08 27.
Artigo
Inglês
| MEDLINE | ID: mdl-27567500
6.
Delamanid for multidrug-resistant pulmonary tuberculosis.
N Engl J Med
; 366(23): 2151-60, 2012 Jun 07.
Artigo
Inglês
| MEDLINE | ID: mdl-22670901
7.
Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.
Clin Infect Dis
; 62(9): 1188-90, 2016 May 01.
Artigo
Inglês
| MEDLINE | ID: mdl-26908794
8.
Building clinical trial capacity to develop a new treatment for multidrug-resistant tuberculosis
Bull. W.H.O. (Print)
; 94(2): 147-152, 2016-2-01.
Artigo
Inglês
| WHOLIS | ID: who-271840